Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis

American Journal of Hematology

Volumn 83, Issue 8, 2008, Pages 614-617

  Kumar, Shaji K ^a   Dingli, David ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Hayman, Suzanne R ^a   Buadi, Francis K ^a   Rajkumar, S Vincent ^a   Litzow, Mark R ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETIC ABNORMALITY; CYTOGENETICS; DIARRHEA; DISEASE COURSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; LABELING INDEX; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; PLASMA CELL; PRIORITY JOURNAL; SURVIVAL; TACHYCARDIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 49149101596     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21191     Document Type: Article

References (23)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657-1664.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med 1983; 308:314-316.
4. Alexanian R, Bonnet J, Gehan E, et al. Combination chemotherapy for multiple myeloma. Cancer 1972;30:382-389.
5. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
6. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348: 1875-1883.
7. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-3136.
8. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51-54.
9. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:600-607.
10. Reece DE, Bredeson C, Perez WS, et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs>/=60 years of age. Bone Marrow Transplant 2003;32:1135-1143.
11. Jantunen E, Kuittinen T, Penttila K, et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: Comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006;37:917-922.
12. Miller CB, Piantadosi S, Vogelsang GB, et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 1996;14:1327-1332.
13. Kusnierz-Glaz CR, Schlegel PG, Wong RM, et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol 1997;15:18-25.
14. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248-1253.
15. Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan - prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. ASH Annu Meet Abstr 2005;106:780.
16. Kumar S, Lacy M, Dispenzieri A, et al. Autologous stem cell transplantation for multiple myeloma in patients over 70 years: A matched comparison with patients under 65 years. ASH Annu Meet Abstr 2005;106:1173.
17. Palumbo A, Triolo S, Baldini L, et al. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. Haematologica 2000;85:508-513.
18. Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000;25:533-539.
19. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (>/=70 years) with multiple myeloma: Influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003;120:413-423.
20. Dumontet C, Ketterer N, Espinouse D, et al. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplant 1998;21:1037-1041.
21. Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993;81:3382-3387.
22. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT European group for blood and marrow transplant. Br J Haematol 1998;102:1115-1123.
23. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.